| US 7,452,897 B2 | ||
| Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases | ||
| Alistair Lochead, Charenton le Pont (France); Mourad Saady, Paris (France); Franck Slowinski, Thieux (France); and Philippe Yaiche, Les Lias (France) | ||
| Assigned to Sanofi-Aventis, Paris (France); and Mitsubishi Pharma Corporation, Osaka (Japan) | ||
| Filed on Mar. 29, 2007, as Appl. No. 11/693,345. | ||
| Application 11/693345 is a continuation of application No. 11/219923, filed on Sep. 06, 2005, granted, now 7,211,581. | ||
| Application 11/219923 is a continuation of application No. PCT/EP2004/003050, filed on Mar. 05, 2004. | ||
| Claims priority of application No. 03290570 (EP), filed on Mar. 07, 2003; and application No. 03290571 (EP), filed on Mar. 07, 2003. | ||
| Prior Publication US 2007/0167455 A1, Jul. 19, 2007 | ||
| Int. Cl. A61K 31/506 (2006.01); A61K 31/444 (2006.01); A61P 3/10 (2006.01); A61P 25/28 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01) | ||
| U.S. Cl. 514—273 [544/320] | 8 Claims |
1. A method for the treatment of a disease selected from the group consisting of Alzheimer's disease, taupathies, non-insulin
dependent diabetes, which comprises administering to a patient in need of said treatment a therapeutically effective amount
of a compound of formula (I) or a pharmaceutically acceptable salt thereof:
 n represents 1 or 2;
R1 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom;
R2 represents a hydrogen atom, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group, a C1-4 alkoxy group;
a C1-2 perhalogenated alkyl group, a benzyl group, a phenethyl group, a benzyloxycarbonyl group, a C1-4 alkoxy carbonyl group, a benzene ring, a naphthalene ring, a quinoline ring, a phthalazine ring, a 5,6,7,8-tetrahydronaphthalene
ring, a pyridine ring, an indole ring, a pyrrole ring, a thiophene ring, a benzenesulfonyl group, a benzoyl group, a pyridazine
ring, a furan ring and an imidazole ring; each of the benzyl group, the phenethyl group, the benzyloxycarbonyl group, the
benzenesulfonyl group, the benzoyl group and the benzene, naplithalene, quinoline, phthalazine, 5,6,7,8-tetrehydronaphthalene,
pyridine, indole, pyrrole and thiophene rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a benzene ring, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro group, a cyano group, an amino group, a C1-6 monoalkylamino group and a C2-10 dialkylamino group;
R3 represents a 2, 4 or 5-pyrimidine ring or a 2,3 or 4-pyridine ring, the rings being optionally substituted by a C1-4 alkyl group, C1-4 alkoxy group or a halogen atom; and
R4 represents a C1-4 alkyl group optionally substituted by a hydroxyl group, a C1-4 alkoxy group or a halogen atom.
|